Assessment of the circulating cell-free DNA marker association with diagnosis and prognostic prediction in patients with lymphoma: a single-center experience-Reference-Cited by-同舟云学术

Assessment of the circulating cell-free DNA marker association with diagnosis and prognostic prediction in patients with lymphoma: a single-center experience

Published:2017-06-16 Issue:8 Volume:96 Page:1343-1351
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Li Mao,Jia Yongqian,Xu Juan,Cheng Xiaomin,Xu Caigang

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-017-3043-5/fulltext.html

Reference34 articles.

1. Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132

2. Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068

3. Mandel P, Metais P (1948) Les acides nucleiques du plasma sanguin chez l'homme. CR Acad Sci Paris 142:241–243

4. Fatouros IG, Destouni A, Margonis K et al (2006) Cell-free plasma DNA as a novel marker of aseptic inflammation severity related to exercise overtraining. Clin Chem 52:1820–1824

5. Tug S, Helmig S, Menke J et al (2014) Correlation between cell free DNA levels and medical evaluation of disease progression in systemic lupus erythematosus patients. Cell Immunol 292:32–39

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of circulating free DNA as a non-invasive biomarker for diffuse large B-cell lymphoma in Egyptian patients;Alexandria Journal of Medicine;2024-07-23

2. Early prognosis prediction in acute myeloid and acute lymphoid leukemia patients using cell-free DNA concentration ratios;Frontiers in Molecular Biosciences;2024-01-22

3. Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment;CLIN CANCER RES;2023

4. Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment;Clinical Cancer Research;2023-06-26

5. Clinical utility of liquid biopsy in canine oral malignant melanoma using cell-free DNA;Frontiers in Veterinary Science;2023-06-20